Additionally, immunotherapy has become the first-line treatment option for advanced NSCLC, either as monotherapy in case of high programmed death-ligand 1 (PD-L1)-expressing tumors (>50%) or in conjunction with platinum-based chemotherapy regardless of the PD-L1 status [5]. Here, CD274 is linked to non-small cell lung carcinoma.